Learnings from early activities under the US Food and Drug Administration’s five-year ALS Science Strategy could be leveraged and applied to therapeutics currently in development, Office of Neuroscience Director Billy Dunn said.
During a 24 August stakeholder webinar on the Accelerating Access to Critical Therapies for ALS Act, Dunn said that even though the amyotrophic lateral sclerosis strategy and the agency’s broader...
“We understand the urgency and the need for effective and safe treatments for ALS. While the overall science strategy and action plan reflects a five-year overall plan, which the law...